BLCO vs. ZBH, SOLV, SNN, PEN, GKOS, STVN, INSP, NARI, IRTC, and NVST
Should you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew (SNN), Penumbra (PEN), Glaukos (GKOS), Stevanato Group (STVN), Inspire Medical Systems (INSP), Inari Medical (NARI), iRhythm Technologies (IRTC), and Envista (NVST). These companies are all part of the "medical equipment" industry.
Bausch + Lomb vs.
Zimmer Biomet (NYSE:ZBH) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment.
In the previous week, Zimmer Biomet had 26 more articles in the media than Bausch + Lomb. MarketBeat recorded 32 mentions for Zimmer Biomet and 6 mentions for Bausch + Lomb. Zimmer Biomet's average media sentiment score of 0.84 beat Bausch + Lomb's score of 0.21 indicating that Zimmer Biomet is being referred to more favorably in the media.
88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 1.0% of Zimmer Biomet shares are owned by company insiders. Comparatively, 0.2% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Zimmer Biomet has a net margin of 11.77% compared to Bausch + Lomb's net margin of -6.62%. Zimmer Biomet's return on equity of 12.99% beat Bausch + Lomb's return on equity.
Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.
Zimmer Biomet currently has a consensus target price of $124.15, indicating a potential upside of 17.95%. Bausch + Lomb has a consensus target price of $20.00, indicating a potential upside of 26.10%. Given Bausch + Lomb's stronger consensus rating and higher possible upside, analysts clearly believe Bausch + Lomb is more favorable than Zimmer Biomet.
Zimmer Biomet has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.
Zimmer Biomet received 866 more outperform votes than Bausch + Lomb when rated by MarketBeat users. Likewise, 67.06% of users gave Zimmer Biomet an outperform vote while only 42.22% of users gave Bausch + Lomb an outperform vote.
Summary
Zimmer Biomet beats Bausch + Lomb on 16 of the 18 factors compared between the two stocks.
Get Bausch + Lomb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bausch + Lomb Competitors List
Related Companies and Tools
This page (NYSE:BLCO) was last updated on 3/4/2025 by MarketBeat.com Staff
